Introduction
============

Human hepatocellular carcinoma (HCC) is the most common malignant tumor in the liver and the third leading fatal cancer.[@b1-ott-11-3293] The prognosis for HCC remains poor, and the latency period is long, mainly due to the propensity for metastatic progression and poor response to pharmacological treatment.[@b2-ott-11-3293] At present, surgical resection remains the only curative method of treatment but is applicable to only 10%--20% of cases, with a 13% survival rate at 3 years.[@b3-ott-11-3293] Chemotherapy and radiotherapy are still the most important regimens in HCC therapy. However, these two regimens are either not effective enough to destroy the cancer cells or cause significant side effects; therefore, the development of new regimen is desirable.

Arsenic trioxide (As~2~O~3~), which is an active ingredient in traditional Chinese medicine, has been used successfully for treating acute promyelocytic leukemia (APL)[@b4-ott-11-3293] and is also effective in the treatment of solid tumors, including human hepatoma and breast cancer.[@b5-ott-11-3293],[@b6-ott-11-3293] However, this compound has not been widely used because of its toxicity. It is necessary to minimize the dosage of As~2~O~3~ without weakening its anticancer effects.

3′-Azido-3′-deoxythymidine (AZT), a powerful inhibitor of reverse transcriptase, has been used in Phase I and II clinical trials, either alone or in combination with other drugs, in the treatment of gastrointestinal cancers, and some cases of tumor regression have been reported.[@b7-ott-11-3293],[@b8-ott-11-3293] In previous studies, we reported that As~2~O~3~ combined with AZT has a significantly synergic effect on inhibiting the hepatoma cell proliferation (combination index \[CI\] \<1) and inducing its apoptosis.[@b9-ott-11-3293] Furthermore, our results showed that As~2~O~3~ combined with AZT also synergically inhibited the migration and invasion of HepG2 cells.[@b10-ott-11-3293],[@b11-ott-11-3293] However, its anticancer targets are largely unknown.

Early growth response protein 1 (Egr-1) is an important nuclear transcription factor, which belongs to the early gene family. Some studies showed that Egr-1 suppressed tumors by regulating downstream target genes such as TGF-β, cyclin D1, c-jun, PTEN, p53, and P21.[@b12-ott-11-3293]--[@b14-ott-11-3293] Shan et al reported that Egr-1 expression was downregulated in hepatocellular carcinoma, and reexpression of Egr-1 decreased cell growth and tumorigenicity in nude mice.[@b15-ott-11-3293] Of note, it has been reported that Egr-1 expression level correlates with sensitivity to chemo-drugs in cancer cells.[@b16-ott-11-3293]

In the present study, we used the electroporation method of Egr-1 siRNA to explore the role of Egr-1 in HepG2 cells treated by As~2~O~3~ combined with AZT, and the effect of Egr-1 on some tumor-associated genes was also observed in an attempt to provide the molecular basis for the clinical application of As~2~O~3~ combined with AZT in hepatocellular carcinoma.

Materials and methods
=====================

Chemicals and reagents
----------------------

AZT and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-liumbromide (MTT) were purchased from Sigma Chemical Co. (St Louis, MI, USA); As~2~O~3~ was obtained from Shui Kou Shan Mining Bureau of Heng Yang Industrial Company (Hengyang, China); other cell culture supplies were purchased from GE Healthcare -- HyClone (Logan, UT, USA); the antibodies to caspase-3, p53, and β-actin were purchased from ImmunoWay Biotechnology Co. (Newark, DE, USA); peroxidase-conjugated AffiniPure goat anti-rabbit IgG (H+L) was purchased from ZSGB-BIO Co. (Beijing, China); and real-time reverse transcriptase polymerase chain reaction (RT-PCR)-related reagents were purchased from Promega Corporation (Fitchburg, WI, USA).

Cell culture
------------

The HHC cell lines HepG2 were purchased from JRDUN Biotechnology (Shanghai) Co. Ltd. (Shanghai, China). The HHC cell lines HepG2 was cultured in DMEM with high glucose content containing 10% heat-inactivated fetal calf serum, 100 IU/mL penicillin/streptomycin at 37°C and incubated in a 5% CO~2~ humidified atmosphere. Cells were harvested in logarithmic phase for experiments.

Cell electrotransfection
------------------------

HepG2 cells were electrotransfected according to the manufacturer's recommendations (Nucleofector I nuclear transfection apparatus and Amaxa^®^ Cell Line Nucleofector^®^ Kit L, Lonza, Basel, Switzerland) and were divided into three groups: mock (adding the same amount of culture medium), negative control (NC; transfection of non-specific sequence), and Egr1-siRNA (transfected with Egr-1 siRNA) groups. The Egr-1 siRNA segment sense strand is 5′-CCCGGUUACUACCUCUUAUTT-3′, and the antisense strand is 5′-AUAAGAGGUAGUAACCGGGTT-3′. Furthermore, a GFP group (HepG2/GFP, transfect green fluorescent protein) was designed to observe the transfection efficiency under fluorescence microscope. The transfection efficiency of Egr-1 siRNA was also detected by real-time quantitative polymerase chain reaction (qPCR) and Western blotting.

Cell proliferation assay
------------------------

Drug treatment was initiated after the cells had begun attaching to the growth surface. The effects of As~2~O~3~ and AZT on HepG2 survival were determined using the MTT reduction assay described earlier, with minor modifications. In brief, 5×10^3^ cells were plated in 96-well plates in 100 mL of a regular medium per well. After 24 h growth, the cells were treated with As~2~O~3~ (2 μmol/L) and AZT (10, 20 μmol/L) for 72 h. Untreated control and treated cells were incubated with 10 μL of MTT (5 mg/mL in serum-free medium) for 4 h before the end of the incubation period. One hundred microliters of lysis solution (10% SDS in 0.01 mol/L of HCl) were then added and another 24 h culture was made. The cell survival fraction was measured at absorbance (A) 490 nm on a microplate reader (Bio-Rad Laboratories Inc., Hercules, CA, USA). Assays were carried out in triplicate. The proliferation and inhibition rate of cells were calculated, respectively, as follows: $$\text{Proliferation~rate}\ (\%) = \frac{\text{Mean~A}490\ \text{of~experiment~A}490}{A490\ \text{of~control}} \times 100\%$$ $$\text{Inhibition~rate}\ (\%) = 1 - \left( \frac{\text{Mean~A}490\ \text{of~experiment}}{A490\ \text{of~A}490\ \text{of~control}} \right) \times 100\%$$

Synergy determination
---------------------

The synergic effect between AZT and As~2~O~3~ was analyzed using the CI method. Concentration effect curves calculated for each drug, both separately and in combination, were applied to determine the amount of each drug, either separately or in combination, required to achieve a given level of effect. The CI was calculated as follows: $$\text{CI} = \frac{\text{IC}_{A,B}}{\text{IC}_{A}} + \frac{\text{IC}_{B,A}}{\text{IC}_{B}}$$IC~A~ and IC~B~ are the concentrations of A and B needed to produce a given level of cytotoxicity when used separately, whereas IC~A,B~ and IC~B,A~ are the concentrations needed to produce the same effect when used in combination.[@b9-ott-11-3293] A CI value of 1 indicates an additive interaction, values less than 1 indicate a synergic action, and values greater than 1 indicate antagonistic interaction.

Apoptosis assessment
--------------------

Detection of apoptotic cells was carried out by annexin V-fluorescein isothiocyanate/propidium iodide (PI) staining. Cells of the three group were plated onto six-well plates (1×10^5^ cells/well) and grown overnight to allow for cell attachment. They were then treated in the absence (control) or presence of As~2~O~3~ (2 μmol/L) + AZT (20 μmol/L) for 48 h. At the end of the treatment, the cells were harvested, washed with PBS, resuspended in 100 μL of binding buffer, and then incubated with 5 μL of annexin V and 5 μL of PI for 30 min at room temperature in the dark according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA). The samples were acquired on a FACScan flow cytometer (BD Biosciences) and analyzed with CellQuest Software (BD Biosciences). The amount of apoptosis was determined as the percentage of annexin V^+^/PI^−^.

Real-time PCR analysis
----------------------

After 48 h of drug treatment, total RNA was extracted from cells using Trizol reagent. Reverse transcription was performed using Promega cDNA Synthesis Master mix (Promega Corporation) with 50 ng RNA per 25 μL of reaction mixture. For real-time PCR, we used the ABI System 7500 fast-real-time PCR (Thermo Fisher Scientific, Waltham, MA, USA) in standard mode. The total 25 μL reaction system contained 12.5 μL qPCR Master Mix, 1 μL forward/reverse primers, 0.25 μL 5-carboxy-X-rhodamine, 8.25 μL ddH~2~O, and 2 μL templates. The experiments were performed three times. PCR products were normalized against the housekeeping gene β-actin, and measurements between samples were compared by cycle threshold (Ct). The primers used in real-time PCR are as in [Table 1](#t1-ott-11-3293){ref-type="table"}. PCR was performed for Egr-1 or β-actin transcription as follows: denaturation at 94°C for 2 min was followed by 40 cycles of denaturation at 94°C for 15 s, annealing at 58°C for 45 s, and elongation at 60°C for 30 s, followed by a final elongation step at 60°C for 2 min.

Immunoblot analysis
-------------------

Western blotting was performed using standard techniques. Three groups of cells were seeded at 1×10^5^ cells/mL in 25 mL culture flasks and then treated with As~2~O~3~ (2 μmol/L) and AZT (20 μmol/L) and further incubated for 48 h. Cells were washed twice with PBS buffer and lysed in 1% Triton lysis buffer (1% Triton X-100, 50 mM Tris--HCl pH 7.4, 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 1 mM Na~3~VO~4~, 1 mM PMSF, and 2 mg/mL aprotinin) on ice, then centrifuged at 10,000 g for 10 min to collect the supernatant. Protein concentrations were determined with a Bio-Rad protein assay. Total proteins 60 μg were subjected to sodium dodecyl sulfate-polyacrylamide gel ectrophoresis (SDS--PAGE) and transferred to polyvinylidine diflouride filter (PVDF) membranes (Hoffman-La Roche Ltd., Basel, Switzerland). Membranes were blocked with 5% skim milk in Tris-buffered saline + Tween (TBST) (10 mM Tris, pH 7.4, 150 mM NaCl, and 0.1% Tween 20) at room temperature for 2 h and incubated with the corresponding primary antibodies at room temperature for 2 h. After washing with TBST, the membrane was reacted with the appropriate horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature. After extensive washing with TBST, proteins were visualized by chemiluminescent reagents. Blots were then detected with Image Lab software.

Statistical analysis
--------------------

Each experiment was performed in triplicate, and all the data were processed with SPSS 17.0 software. The results were analyzed by two-way ANOVA and Tukey's b test. *P*-value \<0.05 was considered statistically significant.

Results
=======

Transfection efficiency
-----------------------

Since the GFP gene is transfected into the cell, the GFP protein can be expressed in the cell and emit green fluorescence. Therefore, the transfection efficiency can be judged by observing the number of green fluorescent cells under fluorescence microscopy. As shown in [Figure 1](#f1-ott-11-3293){ref-type="fig"}, the green fluorescent cells were significantly increased at 10 h, so the transfection efficiency could be detected at 24 h. The qPCR result showed that the transfection efficiency was over 75% ([Figure 2](#f2-ott-11-3293){ref-type="fig"}), which could meet the experimental requirements.

The effects of Egr-1 on HepG2 cell proliferation
------------------------------------------------

After Egr-1 siRNA transfection, an MTT assay was used to detect the proliferation of the three groups. [Table 1](#t1-ott-11-3293){ref-type="table"} shows that the cell proliferation rate of HepG2/si-RNA group was significantly increased at 24 and 48 h compared with the NC group (HepG2/NC) and the mock group (*P*\<0.01). The cell proliferation rate of the NC group at 24, 48, and 72 h decreased slightly, but the difference was not statistically significant compared with the mock group (*P*\>0.05). However, the cell proliferation rate of HepG2/si-RNA group at 72 h was not significantly different compared with the NC group (HepG2/NC) and the mock group, which could be due to the decrease in the effect of silencing Egr-1 ([Table 2](#t2-ott-11-3293){ref-type="table"}).

The effect of the combination of As~2~O~3~ and AZT on growth of HepG2 cells
---------------------------------------------------------------------------

The MTT assay results showed that 2 μmol/L As~2~O~3~ alone had slightly inhibitory effect on the proliferation of HepG2 cells, but there was no statistically significant difference between three groups (*P*\>0.05). Compared with the NC and the mock groups, the inhibition effect of 10 and 20 μmol/L AZT on HepG2/siRNA group was decreased (*P*\<0.05). Compared with the single drug group, 2 μmol/L As~2~O~3~ combined with 10 or 20 μmol/L AZT significantly enhanced the inhibition effect of HepG2 cells of mock and NC groups. The difference was statistically significant (*P*\<0.01). However, after transfection of Egr-1 siRNA, the inhibition effect of the combinations of As~2~O~3~ and AZT on the proliferation of HepG2 cells was dramatically decreased (*P*\<0.05) ([Figure 3](#f3-ott-11-3293){ref-type="fig"}).

Synergic effect of the combination of As~2~O~3~ and AZT
-------------------------------------------------------

The synergic effect of combination of As~2~O~3~ and AZT at 72 h was analyzed by Calcusyn 2.0 software ([Table 3](#t3-ott-11-3293){ref-type="table"}). The results showed that after the HepG2 cells of the non-specific control group and the control group were treated with As~2~O~3~ combined with AZT, the CI values were 0.2\<CI\<0.4, showing strong synergic effect. However, the CI value of the siRNA group was greater than 1, showing antagonistic effect.

Effects of As~2~O~3~ and AZT on apoptosis of HepG2 cells
--------------------------------------------------------

The results of flow cytometry showed that the apoptotic rate of HepG2 cells treated by As~2~O~3~ (2 μmol/L) combined with AZT (20 μmol/L) was significantly higher than that of the control group (*P*\<0.05). Compared with the mock and NC groups, the cell apoptotic rate of HepG2/siRNA group was significantly decreased (*P*\<0.01). The difference between blank control group and NC group was not significant. The results indicated that As~2~O~3~ combined with AZT could promote the apoptosis of HepG2 cells. After silencing Egr-1, the effect was attenuated ([Figure 4](#f4-ott-11-3293){ref-type="fig"}).

The combination of As~2~O~3~ and AZT promotes the expression of Egr-1 mRNA/protein expression
---------------------------------------------------------------------------------------------

As shown in [Figure 5A](#f5-ott-11-3293){ref-type="fig"}, Egr-1 mRNA expression level of Egr-1 siRNA group was significantly lower than that of the NC group and blank control group after electrotransfection with Egr-1 siRNA for 24 h (*P*\<0.01). Furthermore, the Egr-1 mRNA expression level of the Egr-1 siRNA group is only equivalent to about one-tenth before transfection.

As shown in [Figure 5B](#f5-ott-11-3293){ref-type="fig"}, the combination of As~2~O~3~ (2 μmol/L) and AZT (20 μmol/L) significantly upregulated Egr-1 mRNA expression of HepG2 cell compared with the control group at 48 h (*P*\<0.05). There was no significant difference between the NC and mock groups. However, the expression level of Egr-1 mRNA in the Egr-1 siRNA group was also significantly increased under the action of the drug, which may be because the blocking effect of Egr-1 siRNA is attenuated at 48 h. The Western blotting results showed that the protein level of Egr-1 was consistent with the mRNA level ([Figure 6](#f6-ott-11-3293){ref-type="fig"}).

The expression of Egr-1, p53, and caspase-3 in HepG2 cells treated with As~2~O~3~ combined with AZT following Egr-1 siRNA
-------------------------------------------------------------------------------------------------------------------------

The results of qPCR showed that the expression of p53 and caspase-3 mRNA in the Egr-1 siRNA group was significantly lower than that in mock group or HepG2/NC group (*P*\<0.01). There was no significant difference between the mock group and the NC group (*P*\>0.05) ([Figure 7](#f7-ott-11-3293){ref-type="fig"}). The Western blotting results showed that the protein level of p53 and caspase-3 was consistent with the mRNA level ([Figure 8](#f8-ott-11-3293){ref-type="fig"}).

Discussion
==========

Arsenic, a metalloid that is universally distributed in nature, is considered to be one of the most toxic xenobiotics. In the 1970s, arsenic was proven to be a highly effective agent in the treatment of APL, and there has been significant progress since then. Recent in vitro experiments have indicated that As~2~O~3~ might be effective in the treatment of solid tumors, such as hepatoma, gastric carcinoma, and breast carcinoma.[@b17-ott-11-3293]--[@b19-ott-11-3293] In addition, As~2~O~3~ can promote apoptosis and differentiation and inhibit proliferation of cancer cells and telomerase activity.[@b20-ott-11-3293],[@b21-ott-11-3293] However, several reports demonstrated that malignant solid tumors are insensitive to low dose of As~2~O~3~.[@b22-ott-11-3293] Furthermore, toxic effects of high-dose As~2~O~3~ also seriously limits its clinical application. Of note, more and more studies have shown that the combination of As~2~O~3~ with other drugs is effective in enhancing efficacy and reducing the use of doses so as to reduce side effects. In an As~2~O~3~ and tretinoin integrated treatment protocol for patients newly diagnosed with APL, joint treatment showed a synergistic effect and leaded to a high clinical complete remission (CR) rates.[@b23-ott-11-3293],[@b24-ott-11-3293]

It has been proven that AZT has excellent inhibition effects and chemo-therapeutic sensitization on a variety of tumors;[@b25-ott-11-3293]--[@b27-ott-11-3293] one possible mechanism is the inhibition of telomerase activity.[@b28-ott-11-3293] Moreover, it has been reported that Pt-AZT could downregulate Bcl-2 expression and inhibit the growth of hepatocellular carcinoma in mice.[@b29-ott-11-3293] However, the dosage of AZT alone needed in treatment of tumors can cause severe toxic side effects; furthermore, the problem of multiple drug resistance occurs when a large dose is used, so restricting the further application of AZT as a clinical antitumor agent.[@b30-ott-11-3293],[@b31-ott-11-3293] In some recent studies, AZT exhibited significant synergistic therapeutic with other drugs for tumors in a safe dosage range.[@b32-ott-11-3293]--[@b34-ott-11-3293] Chau et al[@b35-ott-11-3293] suggested that the combination of azacytidine with As~2~O~3~ would be a logical drug combination for treatment of AML in the future. Wang et al[@b36-ott-11-3293] reported that the combination of AZT with emodin could co-inhibit the proliferation of leukemia KG-1a cells.

Our previous studies have found that the combination of AZT and As~2~O~3~ has a significant synergistic effect (co-index CI\<1) on hepatocellular carcinoma, which can reduce the side effects and significantly improve the therapeutic effect of the two compounds. According to some clues, single low doses of As~2~O~3~ and AZT did not promote activity caspase-3, but the combination of the two compounds significantly promoted the activity of caspase-3,[@b9-ott-11-3293] the most important mediators of apoptosis.

Egr-1, a zinc finger transcription factor, has been found to be rapidly induced with a broad range of extracellular stimuli, thus mediating growth, proliferation, differentiation, or apoptosis.[@b37-ott-11-3293] Studies have shown that Egr-1 is low in most human malignant tumor cells and the level of Egr-1 expression is associated with a 5-year survival of cancer patients. In addition, Egr-1 is able to increase the sensitivity of cancer patients to radiotherapy and chemotherapy.[@b38-ott-11-3293] However, the role of Egr-1 in HCC is a controversial topic. Peng et al[@b16-ott-11-3293] reported that Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Conversely, Shan et al[@b15-ott-11-3293] reported that reexpression of Egr-1 decreased cell growth and tumorigenicity in nude mice.

In the present study, we found that, after silencing Egr-1, the proliferation rate of HepG2 cells was significantly increased, and the effect of inhibition proliferation and promoting apoptosis of the combinations of As~2~O~3~ and AZT on HepG2 cells was attenuated. In addition, the CI value was greater than 1, showing antagonistic effect. Our further results showed that the combination of As~2~O~3~ with AZT could significantly enhance the expression of p53 and caspase-3, but the effect was decreased after silencing Egr-1. These results suggested that Egr-1, which could control the expression of p53 and caspase-3, may be the key target of the combination of As~2~O~3~ with AZT on treating hepatocellular carcinoma. Although these findings have potential clinical significance, it is still crucial to further investigate interconnections of Egr-1 among associated signaling nets of hepatocellular carcinoma.

This study was supported by National Natural Science Foundation of China (number 81460456) and Natural Science Foundation of Gansu Province (number 1308RJZA169).

**Disclosure**

The authors reports no conflicts of interest in this work.

![The HepG2 cells were transfected with Egr-1 siRNA.\
**Notes:** (**A1**) and (**A2**) show the cells which were observed under phase contrast microscope at 10 and 24 h, respectively, 200×; (**B1**) and (**B2**) show the cells which were observed under fluorescence microscope at 10 and 24 h, respectively, 200×. The transfected cells emitted green fluorescence.\
**Abbreviation:** Egr-1, early growth response protein 1.](ott-11-3293Fig1){#f1-ott-11-3293}

![qPCR method to detect transfection efficiency.\
**Abbreviations:** Egr-1, early growth response protein 1; qPCR, real-time quantitative polymerase chain reaction; RQ, relative quantity.](ott-11-3293Fig2){#f2-ott-11-3293}

![Effect of As~2~O~3~ combined with AZT on cell proliferation inhibition.\
**Notes:** (**A**) AZT = 10 μmol/L; (**B**) AZT = 20 μmol/L. ^a^Compared with transfection before, \**P*\<0.05; ^b^compared with mock, ^\#^*P*\>0.05; ^c^compared with As~2~O~3~ or AZT alone of the same group, \*\**P*\<0.01, ^\#^*P*\>0.05.\
**Abbreviations:** As~2~O~3~, arsenic trioxide; AZT, 3′-azido-3′-deoxythymidine; Egr-1, early growth response protein 1; NC, negative control.](ott-11-3293Fig3){#f3-ott-11-3293}

![Effects of As~2~O~3~ combined with AZT on cell apoptosis.\
**Notes:** ^a^Compared with blank control group, \**P*\<0.05, \*\**P*\<0.01; ^b^compared with HepG2 or HepG2/NC, \*\**P*\<0.01.\
**Abbreviations:** As~2~O~3~, arsenic trioxide; AV FITC-A, Annexin V fluorescein isothiocyanate-area; AZT, 3′-azido-3′-deoxythymidine; Egr-1, early growth response protein 1; LL, lower left; LR, lower right; NC, negative control; PE-A, phycoerythrin-area under the curve; PI, propidium iodide; UL, upper left; UR, upper right.](ott-11-3293Fig4){#f4-ott-11-3293}

![Relative expression of Egr-1 mRNA in HepG2 cells.\
**Notes:** (**A**) Compared with mock or HepG2/NC group, \*\**P*\<0.01. (**B**) ^a^Compared with blank control group, \*\**P*\<0.01.\
**Abbreviations:** Egr-1, early growth response protein 1; NC, negative control.](ott-11-3293Fig5){#f5-ott-11-3293}

![The expression levels of Egr-1 protein in HepG2 cells (n=3).\
**Note:** Compared with control, \*\**P*\<0.01.\
**Abbreviations:** Egr-1, early growth response protein 1; NC, negative control.](ott-11-3293Fig6){#f6-ott-11-3293}

![The effect of Egr-1 on expression of p53 and caspase-3 mRNA in HepG2 cells.\
**Notes:** Mock, adding the same amount of culture medium; NC, transfection of nonspecific sequence; Egr-1 siRNA, transfected with Egr-1 siRNA; compared with mock group or NC group, \*\**P*\<0.01.\
**Abbreviations:** Egr-1, early growth response protein 1; NC, negative control.](ott-11-3293Fig7){#f7-ott-11-3293}

![The effect of Egr-1 on expression of p53 and caspase-3 protein in HepG2 cells.\
**Notes:** Mock, adding the same amount of culture medium; NC, transfection of nonspecific sequence, Egr-1 siRNA, transfected with Egr-1 siRNA; compared with mock group or NC group, \*\**P*\<0.01.\
**Abbreviations:** Egr-1, early growth response protein 1; NC, negative control.](ott-11-3293Fig8){#f8-ott-11-3293}

###### 

Primer sequence

  Gene                                 Primer sequence (5′→3′)
  ------------------------------------ ----------------------------------
  *Egr-1*                              Forward: CAGCTTGGTCAGTGGCCTAGT
  Reverse: AATGTCAGTGTTCGGCGTGG        
  *p53*                                Forward: TCGAAATGTTCCGAGAGCTGAAT
  Reverse: GTCTGAGTCAGGCCCTTCTGTCTT    
  *Caspase-3*                          Forward: AAATACCAGTGGAGGCCGAC
  Reverse: TTTCAGCTAGGCACAAAGCG        
  *β-actin*                            Forward: TGGCACCCAGCACAATGAA
  Reverse: CTAAGTCATAGTCCGCCTAGAAGCA   

###### 

Cell proliferation rate after transfection

  Group         24 h                                                                                                                                               48 h                                                                                                                                              72 h
  ------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  Mock          100.00±10.13                                                                                                                                       100.00±10.29                                                                                                                                      100.00±10.26
  HepG2/NC      97.73±11.67                                                                                                                                        98.14±12.14                                                                                                                                       94.96±10.17
  HepG2/siRNA   135.39±12.14[a](#tfn1-ott-11-3293){ref-type="table-fn"},[b](#tfn2-ott-11-3293){ref-type="table-fn"},[\*](#tfn3-ott-11-3293){ref-type="table-fn"}   137.15±12.3[a](#tfn1-ott-11-3293){ref-type="table-fn"},[b](#tfn2-ott-11-3293){ref-type="table-fn"},[\*](#tfn3-ott-11-3293){ref-type="table-fn"}   95.32±10.31

**Notes:**

HepG2/siRNA and mock groups at the same time point;

HepG2/siRNA and HepG2/NC groups at the same time point;

*P*\<0.05. Data presented as mean ± SD, %, n=3.

**Abbreviation:** NC, negative control.

###### 

CI value of combination of As~2~O~3~ and AZT in the three groups of cells (72 h)

  As~2~O~3~+ AZT (μmol/L)   Groups   Fa      CI
  ------------------------- -------- ------- -------
  2+10                      Mock     0.608   0.174
  HepG2/NC                  0.583    0.193   
  HepG2/siRNA               0.243    1.032   
  2+20                      Mock     0.518   0.261
  HepG2/NC                  0.484    0.303   
  HepG2/siRNA               0.153    3.328   

**Abbreviations:** As~2~O~3~, arsenic trioxide; AZT, 3′-azido-3′-deoxythymidine; CI, combination index; Fa, ratio of the fraction affected; NC, negative control.
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